

SINGAPORE O&G LTD.

(Company Registration No. 201100687M)

CAPITAL INJECTION OF A JOINT VENTURE COMPANY IN MALAYSIA AND USE OF PROCEEDS FROM INITIAL PUBLIC OFFERING

The Board of Directors (the "Board") of Singapore O&G Ltd. (the "Company", together with its subsidiaries, collectively, the "Group") refers to previous announcements released by the Company on 18 March 2021, 30 March 2021 and 13 April 2021 (collectively the "Previous Announcements") in relation to the joint venture between the Company and LYC Mother & Child Centre Sdn Bhd, a wholly-owned subsidiary of LYC Healthcare Berhad, and the incorporation of the Joint Venture Company (the "JV Co"), LYC SOG Mother & Child Sdn. Bhd. (the "Joint Venture").

Further to the Previous Announcements, the Board would like to announce that SOG Mother & Baby Centre Pte. Ltd., a wholly owned subsidiary of the Company, has injected RM 1,960,000 (equivalent to \$\$640,136.00 based on an exchange rate of RM1: \$\$0.3266 as at 30 June 2021) in cash representing the capital injection for its 49% shareholding in the JV Co.

The above capital injection is funded through internal resources by utilising the IPO net proceeds for the expansion of business operations and is not expected to have any material impact on the earnings per share or net tangible assets per share of the Group for the financial year ending 31 December 2021. As of the date of this announcement, the use of IPO net proceeds is as follows:

	Amount Allocated	Amount Utilised	Amount Unutilised
Use of IPO proceeds	S\$'000	S\$'000	S\$'000
Expansion of business operations ¹	3,000	(1,907)	1,093
Investments in healthcare professionals and synergistic businesses ²	6,000	(6,000)	-
Working capital purposes ³	200	(200)	-
Total	9,200	(8,107)	1,093

Notes:

- 1. The amount of S\$1.9 million from the expansion of business operations category has been utilised for the following:
 - S\$1.3 million for set-up cost of new clinics from 2016 to June 2021; and
 - S\$0.6 million for capital injection and incorporation of SOG Mother & Baby Centre Pte Ltd in relation to the Joint Venture.
- 2. The amount of S\$6.0 million from the investments in healthcare professionals and synergistic businesses category has been utilised to pay the first tranche cash consideration of S\$6.0 million for the JL Acquisition in January 2016, in accordance with the terms and conditions of the Framework Agreement dated 4 November 2015 and the Sale and Purchase Agreement dated 31 December 2015.
- 3. The amount of S\$0.2 million from the working capital purposes category has been utilised for the working capitals of SOG Dermatology (Gleneagles) and SOG-Clinic for Children (Gleneagles), as disclosed in the Company's Q1 2019 announcement dated 9 May 2019.

Singapore O&G Ltd.

The above utilisations are in accordance with the intended use of the IPO net proceeds, as stated in the offer document of the Company dated 26 May 2015.

The Company will continue to provide periodic updates on the use of the balance of the proceeds through SGXNet as and when such funds are materially disbursed.

None of the Directors, substantial shareholders or controlling shareholders of the Company, and their respective associates, has any interest, direct or indirect, in the Incorporation, other than through their respective shareholding interests (if any) in the Company.

BY ORDER OF THE BOARD

DR. BEH SUAN TIONG EXECUTIVE CHAIRMAN 30 June 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.